The Benefic Effects of Cannabis on Patients with Multiple Sclerosis
For patients diagnosed with multiple sclerosis, cannabis may be considered an important treatment, according to recent experiments. While the symptomatic changes encountered by multiple sclerosis patients who were given cannabinoid drugs were originally assumed to be dictated solely by psychological factors, later research has shown that cannabis actually decreases muscle spasms and stiffness characteristic of multiple sclerosis sufferers. Short-term and long-term randomised medical trials have confirmed the beneficial effects of cannabis on patients with multiple sclerosis. Visit our website to get free information about Dispensary Deals
The findings of a series of short-term and long-term experiments on the impact of cannabinoids on patients with multiple sclerosis were made public in 2003 by a team of researchers from the Peninsula Medical School in Exeter, UK. About 600 patients with advanced stage multiple sclerosis were actively involved in the research previously performed. Participants were split into two distinctive groups: the first group received equivalent doses of cannabinoid compounds, while the second group received 15 weeks of placebo treatment. Most patients who were given cannabinoids experienced substantial symptomatic changes by the end of the trial, getting less muscle pain and facing milder muscle spasticity (less pronounced muscle spasm). The control group (patients taking placebo medications) experienced no changes in their overall condition, unlike the group receiving cannabinoid compounds during the entire study period.
The study was later replicated in order to affirm the validity of the results and to discard any concerns as to the efficacy of cannabis in ameliorating the symptoms of multiple sclerosis. The subsequent research was carried out over a 12-month period and included the involvement of the same subjects. However, as in the case of the previous experiment, this time the participants were split into 3 distinctive groups instead of 2. The first group received D9-tetrahydrocannabinol (THC) tablets, the active ingredient in cannabis, the second group received natural cannabis extracts, and the third group received placebo drugs.
Patients were thoroughly assessed and tested by a team of physiotherapists and neurologists at the end of the trial. Among the patients in the first sample group, the best outcomes were obtained, with the majority of subjects who received equivalent doses of THC reporting substantial changes in their symptoms. The patients experienced minor improvements in their symptoms in the second research group, while the patients in the third group did not feel any changes in their condition.